AbbVie to Present New Data at 27th EADV Congress

Tuesday, September 04, 2018 | Personnel/Company News , Psoriasis , Research and Publications , AbbVie


AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-16, in Paris.

"While there have been significant advances in the treatment of serious dermatologic diseases in recent years, some patients still do not achieve their desired treatment goals and are in need of additional effective therapeutic options," said Marek Honczarenko MD, PhD, vice president, global immunology development, AbbVie. "AbbVie's data at EADV reflect our unwavering commitment to addressing these ongoing therapeutic challenges for patients and our continued pursuit of innovative medicines that raise treatment expectations and improve upon the standard of care." 

AbbVie will present data from three pivotal Phase 3 trials of risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in patients with moderate to severe psoriasis, including first presentation of the full data results from the IMMvent trial as well as patient-reported outcomes results from ultIMMa-1, ultIMMa-2 and IMMvent.

Additional patient-reported outcomes data from a Phase 2b trial evaluating upadacitinib, an investigational JAK1 inhibitor, in atopic dermatitis will be featured as an oral presentation on Thursday, September 13 at 3:20 p.m. CEST. In addition, efficacy and safety results at week 32 of the Phase 2b trial will be presented. 

Risankizumab and upadacitinib are not approved by regulatory authorities and safety and efficacy have not been established. 

AbbVie will also share long-term efficacy and safety results evaluating HUMIRA in hidradenitis suppurativa (HS) during an oral presentation. Data reporting long-term inhibition of radiographic progression with HUMIRA in psoriatic arthritis will also be featured as an oral ePoster presentation, along with real-world long-term safety and effectiveness data that further support the real-world value of HUMIRA for the treatment of moderate to severe psoriasis. 

HUMIRA is one of the most comprehensively-studied biologics available for immune-mediated diseases, and is supported by more than 20 years of clinical trial experience in immunology.

Next Story

Comments

You must be logged in to leave a comment.